This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joerger, M. Articles by Beijnen, J. H. Search for Related Content PubMed PubMed Citation Articles by Joerger, M. Articles by Beijnen, J. H.

Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors

Authors' Affiliations: ¹ Department of Pharmacy and Pharmacology, Slotervaart Hospital; Departments of ² Medical Oncology, ³ Radiotherapy, and ⁴ Clinical Chemistry, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, the Netherlands; and ⁵ Division of Drug Toxicology, Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands

Requests for reprints: Markus Joerger, Slotervaart Hospital/The Netherlands Cancer Institute, Department of Pharmacy and Pharmacology, Louwesweg 6, 1066 EC, Amsterdam, the Netherlands. Phone: 31-20-512-4657; Fax: 31-20-512-4753; E-mail: apmsj{at}slz.nl.

Background: The aim of this study was to quantitatively assess the effect of anthropometric and biochemical variables and third-space effusions on paclitaxel pharmacokinetics in solid tumor patients.

Materials and Methods: Plasma concentration-time data of paclitaxel were collected in patients with non–small cell lung cancer (n = 84), ovarian cancer (n = 40), and various solid tumors (n = 44), totaling 168 patients. Paclitaxel was given as a 3-hour infusion (n = 163) at doses ranging from 100 to 250 mg/m², or as a 24-hour infusion (n = 5) at a dose of 135 or 175 mg/m². Data were analyzed using nonlinear mixed-effect modeling.

Results: A three-compartment model with saturable elimination and distribution was used to describe concentration-time data. Male gender and body surface area were positively correlated with maximal elimination capacity of paclitaxel (VM_EL); patient age and total bilirubin were negatively correlated with VM_EL (P < 0.005 for all correlations). Typically, male patients had a 20% higher VM_EL; a 0.2 m² increase of body surface area led to a 9% increase of VM_EL; a 10-year increase of patient age led to a 5% decrease of VM_EL; and a 10-µmol increase of total bilirubin led to a 14% decrease of VM_EL. Third-space effusions were not correlated with paclitaxel pharmacokinetics.

Conclusions: This extended retrospective population analysis showed patient gender to significantly and independently affect paclitaxel distribution and elimination. Body surface area, total bilirubin, and patient age were confirmed to affect paclitaxel elimination. This pharmacokinetic model allowed quantification of the covariate effects on the elimination of paclitaxel and may be used for covariate-adapted paclitaxel dosing.

This article has been cited by other articles:

				S. V. Barrett, J. Paul, A. Hay, P. A. Vasey, S. B. Kaye, R. M. Glasspool, and On behalf of the Scottish Gynaecological Cancer Tr Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial Ann. Onc., May 1, 2008; 19(5): 898 - 902. [Abstract] [Full Text] [PDF]

				M. Joerger, A. D.R. Huitema, D. J. Richel, C. Dittrich, N. Pavlidis, E. Briasoulis, J. B. Vermorken, E. Strocchi, A. Martoni, R. Sorio, et al. Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group Clin. Cancer Res., November 1, 2007; 13(21): 6410 - 6418. [Abstract] [Full Text] [PDF]

				R. H.J. Mathijssen, F. A. de Jong, W. J. Loos, J. M. van der Bol, J. Verweij, and A. Sparreboom Flat-Fixed Dosing Versus Body Surface Area Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference? Oncologist, August 1, 2007; 12(8): 913 - 923. [Abstract] [Full Text] [PDF]

				A. Sparreboom and W. D. Figg Identifying sources of interindividual pharmacokinetic variability with population modeling. Clin. Cancer Res., April 1, 2006; 12(7): 1951 - 1953. [Full Text] [PDF]